Contributor Disclosures for Bone Marrow Failure

Role Name Disclosure Details Author  Emmanuel C Besa, MD, Professor, Department of Medicine, Division of Hematologic Malignancies, Kimmel Cancer Center, Thomas Jefferson University Nothing to disclose Details Coauthor  Ulrich Woermann, MD, Consulting Staff, Division of Instructional Media, Institute for Medical Education, University of Bern, Switzerland Nothing to disclose Details Medical Editor  Thomas H Davis, MD, FACP, Associate Professor, Fellowship Program Director, Department of Internal Medicine, Section of Hematology/Oncology, Dartmouth Medical School Nothing to disclose Details Pharmacy Editor  Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine Nothing to disclose Details CME Editor  Rajalaxmi McKenna, MD, FACP, Consulting Staff, Department of Medicine, Southwest Medical Consultants, SC, Good Samaritan Hospital, Advocate Health Systems Nothing to disclose Details Chief Editor  Koyamangalath Krishnan, MD, FRCP, FACP, Dishner Endowed Chair of Excellence in Medicine, Professor of Medicine and Chief of Hematology-Oncology, Program Director, Hematology-Oncology Fellowship, James H Quillen College of Medicine at East Tennessee State University Nothing to disclose Details CONTRIBUTOR DISCLOSURE FORM Contributor Name: Emmanuel C Besa  DECLARATION STATEMENT I and/or my spouse/partner have no financial interest with any organization that could be perceived as a real or apparent conflict of interest in the context of the subject of this activity. I and/or my spouse/partner have a financial interest/arrangement with one or more organization(s), including but not limited to the organization(s) supporting this activity, that could be perceived as a real or apparent conflict of interest in the context of the subject of this activity. COMMERCIAL INTEREST (Name of Organization) Self Spouse/ Partner NATURE OF RELEVANT FINANCIAL RELATIONSHIP What was received?* For what role?** Off label or investigational use of medication Revlimid in non-5q- syndrome MDSExjade in transfusion overload in MDS Contributor Disclosure Contributor: Contributor Disclosure: Ulrich Woermann, Coauthor  The contributor discloses no conflict of interest.  Contributor Disclosure Contributor: Contributor Disclosure: Thomas H Davis, Medical Editor  The contributor discloses no conflict of interest.  CONTRIBUTOR DISCLOSURE FORM Contributor Name: Francisco Talavera  DECLARATION STATEMENT I and/or my spouse/partner have no financial interest with any organization that could be perceived as a real or apparent conflict of interest in the context of the subject of this activity. I and/or my spouse/partner have a financial interest/arrangement with one or more organization(s), including but not limited to the organization(s) supporting this activity, that could be perceived as a real or apparent conflict of interest in the context of the subject of this activity. COMMERCIAL INTEREST (Name of Organization) Self Spouse/ Partner NATURE OF RELEVANT FINANCIAL RELATIONSHIP What was received?* For what role?** Off label or investigational use of medication Contributor Disclosure Contributor: Contributor Disclosure: Rajalaxmi McKenna, CME Editor  The contributor discloses no conflict of interest.  CONTRIBUTOR DISCLOSURE FORM Contributor Name: Koyamangalath Krishnan  DECLARATION STATEMENT I and/or my spouse/partner have no financial interest with any organization that could be perceived as a real or apparent conflict of interest in the context of the subject of this activity. I and/or my spouse/partner have a financial interest/arrangement with one or more organization(s), including but not limited to the organization(s) supporting this activity, that could be perceived as a real or apparent conflict of interest in the context of the subject of this activity. COMMERCIAL INTEREST (Name of Organization) Self Spouse/ Partner NATURE OF RELEVANT FINANCIAL RELATIONSHIP What was received?* For what role?** Off label or investigational use of medication